AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Stock-Based Compensation Expense by Quarter
Stock-Based Compensation Expense ($M) ($M)
AbbVie Stock-Based Compensation Expense: $166M in Q2 2026, down 7.3% from a year earlier.
Latest, Q2 2026
166
Period ended Jun 30, 2026
Change on a year earlier
-7.3%
179 in Q2 2025
History
46 quarters
Since Q1 2015
Sources
37
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-03) ↗
Reported in Form 10-Q / 10-K Consolidated Statements of Cash Flows.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). AbbVie Stock-Based Compensation Expense ($M), quarterly Q1 2015–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/cap-sbc-exp
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.